221 related articles for article (PubMed ID: 33344108)
1. Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy.
Rider PJF; Uche IK; Sweeny L; Kousoulas KG
Curr Clin Microbiol Rep; 2019 Dec; 6(4):193-199. PubMed ID: 33344108
[TBL] [Abstract][Full Text] [Related]
2. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
4. Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors.
Hong B; Sahu U; Mullarkey MP; Kaur B
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062322
[TBL] [Abstract][Full Text] [Related]
5. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.
Li QX; Liu G; Zhang X
Curr Pharm Biotechnol; 2012 Jul; 13(9):1773-85. PubMed ID: 21740353
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
7. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
8. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic herpes simplex virus and immunotherapy.
Ma W; He H; Wang H
BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H; Hamada H; Nakano K; Kwon H; Tahara H; Cohen JB; Glorioso JC
Curr Cancer Drug Targets; 2018; 18(2):162-170. PubMed ID: 28176649
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic effect of dual fluorescent-labeled oncolytic herpes simplex virus type 1 on mouse tumorigenic cell lines.
Abdoli S; Roohvand F; Teimoori-Toolabi L; Shayan S; Shokrgozar MA
Res Pharm Sci; 2019 Feb; 14(1):27-35. PubMed ID: 30936930
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA sequencing reveals a strong connection between
Ravirala D; Pei G; Zhao Z; Zhang X
Mol Ther Oncolytics; 2021 Dec; 23():330-341. PubMed ID: 34786476
[TBL] [Abstract][Full Text] [Related]
13. Replicative oncolytic herpes simplex viruses in combination cancer therapies.
Post DE; Fulci G; Chiocca EA; Van Meir EG
Curr Gene Ther; 2004 Mar; 4(1):41-51. PubMed ID: 15032613
[TBL] [Abstract][Full Text] [Related]
14. "Armed" oncolytic herpes simplex viruses for brain tumor therapy.
Todo T
Cell Adh Migr; 2008; 2(3):208-13. PubMed ID: 19262110
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy using herpes simplex virus: how far have we come?
Sokolowski NA; Rizos H; Diefenbach RJ
Oncolytic Virother; 2015; 4():207-19. PubMed ID: 27512683
[TBL] [Abstract][Full Text] [Related]
16. Herpes Simplex Virus 1 Infection Promotes the Growth of a Subpopulation of Tumor Cells in Three-Dimensional Uveal Melanoma Cultures.
Valyi-Nagy T; Fredericks B; Ravindra A; Hopkins J; Shukla D; Valyi-Nagy K
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045986
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex Virus.
Joo KJ; Li H; Zhang X; Lerner SP
Bladder Cancer; 2015 Apr; 1(1):81-90. PubMed ID: 30561438
[TBL] [Abstract][Full Text] [Related]
18. Targeted oncolytic herpes simplex viruses for aggressive cancers.
Wong J; Lee C; Zhang K; Rennie PS; Jia W
Curr Pharm Biotechnol; 2012 Jul; 13(9):1786-94. PubMed ID: 21740360
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.
Sanchala DS; Bhatt LK; Prabhavalkar KS
Front Pharmacol; 2017; 8():270. PubMed ID: 28559846
[TBL] [Abstract][Full Text] [Related]
20. The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.
Kloker LD; Berchtold S; Smirnow I; Schaller M; Fehrenbacher B; Krieg A; Sipos B; Lauer UM
Neuroendocrinology; 2019; 109(4):346-361. PubMed ID: 31280274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
